O-glycoside Patents (Class 514/25)
  • Patent number: 11000535
    Abstract: A composition for inhibiting a liver tumor in an organism is disclosed. The composition includes an activator being 1,2,3,4,6-penta-O-galloyl-Beta-D-glucopyranoside (PGG), wherein PGG is extracted from at least one of Paeonia lactiflora Pall. and Galla Chinesis.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 11, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yi-Ming Chen, Chia-Hung Yen, Chung-Kuang Lu
  • Patent number: 10988731
    Abstract: A method of creating a protein rich conditioned medium. The method includes culturing mesenchymal stem cells in a container utilizing a first growth medium, allowing a time period for proliferation of the mesenchymal stem cells until a desired level of confluence is achieved in the container, discarding a supernatant from the container, adding a second medium to the container, incubating the mesenchymal stem cells, and collecting the conditioned medium. The method produces significantly higher quantities of byproducts secreted by the mesenchymal stem cells. Byproducts are usable for wound healing, disease treatment, cosmetic, or other beneficial effects when applied or otherwise delivered to a patient.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 27, 2021
    Assignee: HOPE BIOSCIENCES, LLC
    Inventors: Hyeonggeun Park, Fred Haisam Khoury
  • Patent number: 10966918
    Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 6, 2021
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 10959929
    Abstract: The present disclosure relates to cosmetic agents which, in addition to ethanol and fragrances, contain at least one fixing agent mixture for the fragrances and have a high and long-lasting deodorizing action. Furthermore, the present disclosure relates to the use of these agents for the treatment of body odor.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 30, 2021
    Assignee: Henkel AG & Co. KGaA
    Inventor: Thomas Doering
  • Patent number: 10953027
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 23, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • Patent number: 10953040
    Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?-lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 23, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Charles V. Rice
  • Patent number: 10940159
    Abstract: A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 9, 2021
    Inventors: James Trinca Green, William Owen Wilkison
  • Patent number: 10941111
    Abstract: Disclosed herein is a continuous manufacturing process for lomustine that has a short residence time and 63 percent yield. Major advantages of this process are that the total production cost for lomustine is lower, the product is higher quality, and the manufacturing operation is safer for production personnel.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Purdue Research Foundation
    Inventors: David H Thompson, Robert Graham Cooks, Christina Ramires Ferreira, Zinia Jaman
  • Patent number: 10927148
    Abstract: Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 23, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Christopher R. So, Kathryn J. Wahl
  • Patent number: 10898424
    Abstract: The present invention relates to a blend comprising palmitoyl tripeptide-5, an algae extract, panthenol, water and optionally pullulan and/or sodium hyaluronate.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 26, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Mathias Gempeler, Dominik Imfeld, Dirk Weber, Dominique Crestia
  • Patent number: 10874749
    Abstract: A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition is suitable for administration to a patient comprising injecting the AAV or other human compatible virus into the brain by intracranial stereotaxic injunction; wherein the AAV's encoding for the Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof enhance and/or normalize levels of GM1 in neurons, providing both therapeutic relief and disease modifying effects in specific areas of the brain relevant to particular neurodegenerative diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 29, 2020
    Assignee: Thomas Jefferson University
    Inventors: Jay S. Schneider, David W. Anderson
  • Patent number: 10870021
    Abstract: Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 22, 2020
    Assignee: NOORIK BIOPHARMACEUTICALS AG
    Inventors: Iker Navarro, Satish Khanna
  • Patent number: 10822430
    Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 3, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10822367
    Abstract: The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: November 3, 2020
    Assignee: PHYTO CORPORATION INC.
    Inventors: Deuk-Hoi Kim, Mee-Hyang Kweon, Eun-Ah Cho, Joon Soo Kim, Hyun Joo Yoon, Seon Yeong Park
  • Patent number: 10787476
    Abstract: An object of the present invention is to provide glycoamino acid as an amino acid precursor with improved properties (particularly water-solubility, stability in water, bitter taste etc.). The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 29, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Wataru Kurosawa, Risa Ubagai
  • Patent number: 10752650
    Abstract: The subject invention provides a novel SL that is widely applicable to various fields including food or beverages, cosmetics, pharmaceuticals, and quasi-drugs. A sophorolipid compound represented by Formula (I) below: (in Formula (I), R1 represents H or a methyl group; R3 and R4 each represents H or an acetyl group; one of five R5 is a saturated or unsaturated fatty acid residue that may have an OH group, and the remaining four R5 are H; R2 represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds; R6 represents hydroxy, or may form a single bond together with one of five R7 in the compound represented by Formula (II) below) (in Formula (II), R1? represents H or methyl group; R3? and R4? each represents H or an acetyl group; R2? represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds).
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: August 25, 2020
    Assignee: Saraya Co., Ltd.
    Inventors: Michiaki Araki, Yoshihiko Hirata
  • Patent number: 10723750
    Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 28, 2020
    Assignees: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZW
    Inventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
  • Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang
  • Patent number: 10696662
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Patent number: 10682346
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 16, 2020
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 10683525
    Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 16, 2020
    Assignee: TECHNISCHE UNIVERSITÄT GRAZ
    Inventors: Christiane Luley, Thornthan Sawangwan, Bernd Nidetzky, Mario Müller
  • Patent number: 10603300
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 31, 2020
    Inventors: Saskia Kley, Dania Birte Reiche
  • Patent number: 10568897
    Abstract: A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in enhancing growth in an animal is disclosed. The composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 25, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Wen-Chin Yang, Lee-Tian Chang
  • Patent number: 10568352
    Abstract: The disclosure provides nutritional compositions including a blend of amino acids and polyphenols. These nutritional compositions find use, for example, in treating and preventing EMS and laminitis in equines, as well as generally promoting animal health.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 25, 2020
    Assignee: Wiser Concepts, LLC
    Inventor: Delia Nash
  • Patent number: 10561678
    Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 18, 2020
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 10555960
    Abstract: Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-2-hydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 11, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventor: Ramil Y. Baiazitov
  • Patent number: 10538794
    Abstract: This disclosure relates to libraries of oligosaccharides comprising multiple individual oligosaccharides derived from cells that contain a tag or detectable marker. In certain embodiments, the tag or detectable marker is an oxygen linked to the oligosaccharides through the first carbon of a sugar ring. In certain embodiments, the disclosure relates to methods of generating the libraries of oligosaccharides using saccharides, e.g., monosaccharides, or a disaccharide, in which hydroxyl groups are chemically acetylated.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 21, 2020
    Assignee: Emory University
    Inventors: Tongzhong Ju, Richard Cummings, Matthew Kudelka
  • Patent number: 10525162
    Abstract: The present invention provides a biocompatible hydrogel composition comprising glycolipids and silk fibroin (SF) wherein glycolipid is preferably sophorolipids (SL). The said composition is useful in preparation of 3D scaffold for use in tissue engineering, and in the biomedical field. The present invention also provides a process for preparing such a composition and a process for acceleration of gelation time of silk fibroin (SF) in the presence of sophorolipid.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Parul Dubey, Philem Pushparani Devi, Anuya Amol Nisal, Asmita Ashutosh Prabhune
  • Patent number: 10512641
    Abstract: Described herein are methods for treating cancer in a subject in need thereof by administering chloroquine, or a salt or prodrug thereof, optionally with another agent that promotes Par-4 production to induce prostate apoptosis response-4 (Par-4) production by host cells, particularly non-cancerous host cells, to promote apoptosis in cancer cells, including androgen insensitive prostate cancer cells.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 24, 2019
    Assignee: University of Kentucky Research Foundation
    Inventor: Vivek M. Rangnekar
  • Patent number: 10493013
    Abstract: The present invention provides an external-use liquid skin-conditioning composition that not only reduces the sticky and friction sensations caused by the inclusion of tranexamic acid, but also has a rich body without feeling slimy and softens the skin after use. The composition comprises (A) 0.5 to 5 mass % of at least one item selected from a group consisting of tranexamic acid and derivatives thereof and (B) 0.005 to 1.5 mass % of carboxymethylcellulose, has a viscosity of no greater than 500 mPa s at 30° C., and is transparent or semitransparent with an L value between 50 and 100 inclusive. Preferably the composition contains only carboxymethylcellulose as a thickener.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: December 3, 2019
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Chihiro Yasuda, Kazunobu Suzuki
  • Patent number: 10493087
    Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: December 3, 2019
    Assignee: The United States of America, as represented by National Institute of Health
    Inventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
  • Patent number: 10463891
    Abstract: The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: November 5, 2019
    Assignee: Symrise AG
    Inventors: Martina Herrmann, Holger Joppe, Paolo Pertile, Lorenzo Zanella
  • Patent number: 10449224
    Abstract: This invention relates to methods and compositions for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans (isolated in form of the lignan precursor Secoisolariciresinol diglucoside (SDG) directly from whole-grain flaxseed or chemically synthesized directly into the mammalian, readily metabolizable forms, Enterodiol (ED) or Enterolactone (EL). Such pathological condition result from oxidative lung injury such as ischemia-reperfusion injury (related to lung transplantation), radiation fibrosis and cancer. Specifically, the invention is directed to the use of flaxseed lignans in the treatment of acute and chronic lung injury as well as cancer.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: October 22, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo Christofidou-Solomidou
  • Patent number: 10435692
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 8, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 10383847
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 20, 2019
    Inventors: Dennis M. Brown, Ian Nisbet
  • Patent number: 10368569
    Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: August 6, 2019
    Assignee: MONTERO GIDA SANAYI VE TICARET A.S.
    Inventors: Ahmet Toksöz, Zafer Toksöz, Onur Mutlu, Ali Türkyilmaz, Gülay Yelken, Merve Zan
  • Patent number: 10301344
    Abstract: Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl}-5-C-(hydroxymethyl)-?-L-idopyranose L-proline (a compound of formula (I)), a monohydrate and a type A crystal thereof, and a preparation method therefor. The obtained type A crystal of the compound of formula (I) has good chemical stability and crystal stability, and the crystallization solvent used has low toxicity and low residue, so the type A crystal can be better used in clinical treatment.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: May 28, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang Sun, Guaili Wu, Changshan Guo, Yun Lu, Yuxia Wu, Lingjia Shen
  • Patent number: 10293013
    Abstract: The present invention provides a method of obtaining Psidium guajava leaf extract standardized to phytochemicals. The extract obtained is highly soluble in water, and contains standardized phytochemicals such as, guijavarin specifically saponins and polyphenols, which may be used in food and beverage products. The method involves the specific method of filtration to obtain highly purified form of phytochemical. The extract obtained is subjected to bio-activity guided fractionation to isolate different compounds to obtain phytochemical enriched fraction followed by purification and isolation of the single phytochemical from the enriched bioactive fraction. The phytochemical is identified as guijaverin, which also exhibits anti-diabetic activity. The Psidium guajava leaf extract is useful in food and beverage industries and is used in different formulations such as chocolates, capsules, and aqua based supplement drinks.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 21, 2019
    Inventors: Venkatachalam Hariharan, Pradeepkumar Siddavvanahalli Virupakshappa, Kanchana Hariharan, Paranjothi Kanni, Dipshikha Chakravortty
  • Patent number: 10208051
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 19, 2019
    Assignee: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • Patent number: 10206860
    Abstract: Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 19, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Nilza Shimohirao, Odete Tieko Yamane, Joao Abel Correia, Katrin Costa, Enzo Utima, Andre S. David
  • Patent number: 10174132
    Abstract: The invention provides an efficient modular chemical synthesis for heparan sulfate oligosaccharides based on orthogonal protection strategies. Modular disaccharide building blocks, themselves the product of a novel combinatorial synthesis, are combined in numerous ways to produce a range of oligosaccharides.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 8, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Geert-Jan Boons, Andre Venot, Sailaja Arungundram, Kanar al-Mafraji
  • Patent number: 10080752
    Abstract: The present invention provides methods for treating tumors of the brain by administering the compounds of the Formula A and particularly N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. In the methods of the invention, the compounds disclosed herein were surprisingly found to cross the blood brain barrier. The method of the present invention further relates to the treatment of cancers of any type potentially responding to EGFR, HER2, VEGFR2, or Src family kinase inhibitors and that are found in the brain.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 25, 2018
    Assignee: KADMON CORPORATION, LLC
    Inventor: Samuel Waksal
  • Patent number: 10077444
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 18, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kevin Fitzgerald, Alfica Sehgal, Brian Bettencourt, Gregory Hinkle
  • Patent number: 10065982
    Abstract: The present invention provides a high-purity acid-form sophorolipid (SL)-containing composition characterized by substantially not containing acetic acid. The high-purity acid-form SL-containing composition can be produced, for example, by the following method: (i) adjusting the pH of a partially purified acid-form SL-containing composition to an acidic range; and (ii-a) subjecting an acidified partially purified acid-form SL-containing composition obtained in step (i) to chromatography to acquire a fraction containing an acid-form SL, or (ii-b) leaving the acidified partially purified acid-form SL-containing composition obtained in step (i) to stand under a low-temperature condition to acquire a resulting gelled object.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: September 4, 2018
    Assignee: Saraya Co., Ltd.
    Inventors: Yoshihiko Hirata, Mizuyuki Ryu, Hitoshi Ito, Michiaki Araki
  • Patent number: 10016358
    Abstract: The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: July 10, 2018
    Assignee: ROLF KULLGREN AB
    Inventor: Bjorn Andersch
  • Patent number: 10011627
    Abstract: C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: July 3, 2018
    Assignee: YOUNGENE THERAPEUTICS CO., LTD
    Inventors: Huijuan Zhong, Jianchun Liao, Hongping Yu, Yaochang Xu, Qing Li, Jianghua Chen, Peng Gao, Songliang Tan, Shaobao Wang
  • Patent number: 10011628
    Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: July 3, 2018
    Assignee: ADENOVIR PHARMA AB
    Inventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
  • Patent number: 9980928
    Abstract: Hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), and compositions thereof, are useful as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 29, 2018
    Inventors: Josep R. Prous, Neus Serradell, Ramon Flores, Noemi Garcia-Delgado, Marcel-li Carbo Banus
  • Patent number: RE46907
    Abstract: Disclosed is a composition comprising a derivative of NDGA and at least one metabolic modulator. The composition can be in a unit dose form or kit. The composition can comprise at least two metabolic modulators. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer, by administering a composition of the invention. In various embodiments of the invention subjects with cancer achieve prolonged survival and/or diminution in the size of their malignancies and cancer metastasis.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 26, 2018
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih C. Huang, Kotohiko Kimura
  • Patent number: RE46955
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: July 17, 2018
    Assignee: Progen PG500 Series Pty Ltd
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond